Get started

Biotech

Is MRNA revealing major upside opportunity? BULL or BEAR? Today we're looking at MRNA aka Moderna, the darling biotech that might be the savior of us all should they produce an mRNA vaccine that could be more easily produced and distributed at scale than a traditional vaccine candidate. Reading into this story I've been intrigued, especially with the nice patterns forming in this chart with an easy to identify Impulse wave and a correction pattern currently forming. Unfortunately, this is always the riskier proposition and we must consider our Bull and Bear cases objectively so that we have a plan. As you'll see, we recently bounced off the 0.5 fib retracement from the all-time high of $95 all the way back to $53. Looks like a healthy bounce off that level. But we should almost always expect it. There is nothing to get excited about until we see a more convincing bounce with volume. While I love the long term pattern being set up in this chart with that hopeful bull target of $136.99, there's a lot of work to make up and resistance to overcome before we get anywhere close. The declining volume is something to watch out for. If you zoom in you'll see the upward channel off the bounce paired with the declining volume. This would indicate that short term we'll retest the low, and if we're lucky we can get a buying opportunity off that low and off the 0.618 at $43.50. Set your ladders appropriately and always calculate your stop loss according to risk preference fo % loss below average calculated cost. If you plan your buy levels and amount in advance you can easily calculate the average buy price and then subtract 20% for example to reach a reasonable stop loss which shields you from setting a stop loss too high and missing the following run, or setting it too low and losing more than you are willing to. Meanwhile, looking at the long term trend, we'll have some trading potential on the stock, but need to look for some volatility within the current correction pattern. Given the sharp increase and resulting decrease, one can assume we might see similar moves again in the future, though there's nothing to indicate exactly when at the moment until we see a better channel or a convincing wedge reveal itself. The longer-term trend bodes well for your everyday investor who's willing to take some loss for a very large potential gain. Should Moderna create their mRNA based vaccine in time and be successful with distribution, the value of this company would quickly skyrocket. I'm willing to bet on an optimistic future and I'm definitely keeping an eye on this opportunity with the buy ladders I've mentioned indicated. What's your Bull and Bear case on Moderna? How would you play this in the short and long term?
NASDAQ:MRNA
by Shadowfigure
2
$ABT Cup and Handle Pattern Formation on DailySentiment: Bullish Reasons: Technical Analysis & News Catalyst News has just been released that $ABT has been approved by the U.S to begin working on a 5$ rapid COVID-19 antigen test. I find this to be huge considering the inconvenience in searching for a COVID testing facility in certain places in the U.S as well as the discomfort associated with the actual process. In addition price action is just nice if Im being honest. It has underwent a long series of consolidation and converging trendlines and is due for a breakout.
NYSE:ABTLong
by DannyNoburu
Hold your breath peopleIf you have viewed my posts about IBIO , you would have witness the long term yellow line cutting through the 1.6-1.8 price point. Either this drop is to retest the long term channel or ... well... good luck to those that still believe in the company. I like the innovative company and the CEO's track record and was invested since $0.3. I really appreciate the person that referred me to IBIO on yahoo chatroom in Feb. I have started to trimmed my position when this started to breaking through all the support level like a hot knife through butter below the $3 dollar range. Wish the bulls good luck! just need one proper PR and this beast will rocket. stay safe! Side thought: I have seen in many chatroom and witness many high PT for all different kind of ticker (i guess you reading this have as well). Especially, 'this company has XXX product and it deserve XXX price' ,' this company will save the world '. I mean i am sure that biotech companies have all the smartest people in the world and they deserve tremendous net worth for all they have done for humanity, but unfortunately, this is a money society.Invest safe and wise people. Companies pulling moves like Novavax and Overstock are rare; i believe it is more luck than any other reason.
AMEX:IBIO
by jordanadriano
4
breaking out in a few days? PT 17-18In my previous idea, i stated that IBIO would consolidate around mid 4 area until next breakout but it was not how it ended. With Russian news and insider dumping, IBIO went back all the way to its breakout point. Currently, it is touching the trend drawn all the way from the beginning of the year that connects two breakout point (green line, breakout points are drawn in blue). Is it ready for a run? If it runs, i expect PT of 17-18 then retracement. retracement levels shown on figure (10 dollar, worst case scenario $6-7)
AMEX:IBIOLong
by jordanadriano
6
NSPR still dippingOkay I'm gonna start off with the news News -NSPR beat earnings by 44%, yet still losing money. It has been making more money due to its past performance and not losing as much. We can project that they might be profitable next year. -Their offering that was held in June came out that it was so they can remain compliant with the exchange. That Friday they have became fully compliant so they won't get delisted. -On their earnings report they got mostly compliant FDA IDE approval, yet on that they will get fully compliant FDA IDE approval in 45days. This should be on the 27th, so next week, which I labeled on the graph. -Upcoming catalist: they hope to get into the France and China markets soon. Plus with approval in Brazil we could see that profit from the company in q4/ another earnings beat. Maybe over 100%, yet with COVID not sure, but certain in q1 next year. TA -Not sure what to say since an earnings beat should have pushed the price higher, yet we saw a sell off with no FDA IDE approval to common investors liking. At the same time the volume showed it being very low compared to the past showing its just small sellers and yesterday someone bought 200k shares touching our old trading zone. -the low at .4194 was in the middle of the gap of the intial drop from .80 to .39 then gaping up to .42-.47 Final thoughts I'm DCAing this stock and think its gonna pay off pretty soon. Recent SEC filing shows that their CFO has sign a contract starting in 2022 that he will get an annual renewal of his job. This shows there is some long term potential if a CFO is entering this contract and wants to see growth in this company or he will get fired. There was alot more in the earnings report like and they don't want to do any more offerings and they also have alot of cash on hand to play with, so upside potential is pretty high.
NLong
by nathanielx9
ArcticZymes turnaround & firing on all cylindersThe Turnaround of ArcticZymes is now definitive. For the second quarter we see impressive growth and the company is firing on all cylinders. Opex (cost) going down while earnings as well as profits surge. ArcticZymes Q2 report Sales of NOK 44.3 million (16.9) +262% EBITDA of NOK 27.2 million (-0.5) Cash-flow for the Q2 was NOK 20.4 million (-6.8) Cash at hand NOK 56,1 million Gross margin 90% CEO Jethro Holter says in the earnings call: "The main growth driver has been sales of the Salt Active Nuclease (SAN) products to the therapeutics segment. The SAN products continue to attract new customers who are developing gene therapies and vaccines. Furthermore, our well-established customers are regularly submitting substantially larger orders as they advance their development programs." Full report pdf here: newsweb.oslobors.no text: newsweb.oslobors.no
OSL:AZTLong
by kulturdesken
2